Jun 2025 (Q2 FY25) — Aug 6, 2025
Coca-Cola Europacific Partners Q2 FY25 — Europe returns to volume growth, Indonesia trims revenue guide to 3-4%
Read the full callCoca-Cola Europacific Partners earnings: last reported Wed, 6 Aug 2025, for the quarter ended Jun 2025.
Price
1Y: $90.54 on 17 Oct 2025 → $111.87. High $112.4 (16 Oct 2026), low $85.43 (7 Jan 2026).
Overview
Call summaries
Coca-Cola Europacific Partners Q2 FY25 — Europe returns to volume growth, Indonesia trims revenue guide to 3-4%
Read the full callEvery analysed call
Financials
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 13,342 | 14,075 | 16,212 | 24,781 | 23,322 | 23,512 | 22,975 | 25,344 |
| Fixed assets | 4,452 | 4,724 | 4,737 | 5,944 | 5,547 | — | — | — |
| Total assets | 20,857 | 20,991 | 23,606 | 32,947 | 31,265 | 32,326 | 32,310 | 35,100 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2,068 | 2,139 | 1,828 | 2,398 | 3,127 | 3,101 | 3,180 | 3,470 |
| Cash from investing | -682 | -673 | -454 | -6,348 | -688 | -1,035 | -2,033 | -743 |
| Cash from financing | -1,442 | -1,463 | 123 | 3,725 | -2,428 | -2,013 | -1,011 | -3,396 |
| Capital expenditure | -601 | -568 | -427 | -395 | -533 | -743 | -822 | -881 |
| Free cash flow | 1,467 | 1,571 | 1,401 | 2,002 | 2,594 | 2,358 | 2,358 | 2,589 |
No filings in the last 12 months.
No officer, director or 10% owner of CCEP filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow COCA-COLA EUROPACIFIC PARTNERS plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading